STOCK TITAN

BioXcel Therapeutics Inc - BTAI STOCK NEWS

Welcome to our dedicated news page for BioXcel Therapeutics (Ticker: BTAI), a resource for investors and traders seeking the latest updates and insights on BioXcel Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioXcel Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioXcel Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.95%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.33%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.57%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.08%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.59%
Tags
conferences
BioXcel Therapeutics Inc

Nasdaq:BTAI

BTAI Rankings

BTAI Stock Data

86.23M
21.71M
27.06%
28.53%
10.33%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New Haven

About BTAI

bioxcel therapeutics, inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. the company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. the company's two most advanced clinical development programs are bxcl501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and bxcl701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.